BCT TOR Week ended 31 Jul 2026

Weekly Investor Report

BriaCell Therapeutics Corp. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 4.82 CAD
-4.2% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -10.5% below the Trend Line and sits at 6.4% of its 52-week range. The latest completed week returned -4.2%, after a 5.9% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal.

Setup score 24 out of 100
Latest Close 4.82 CAD 31 Jul 2026
1W Return -4.2% latest completed week
4W Return 5.9% short-term follow-through
12W Return -15.9% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 39.17% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -4.2% Latest completed week; four-week move 5.9%. Indicator stack 0/75 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 39.17% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 51/100 17 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -10.5% below the Trend Line and sits at 6.4% of its 52-week range. The latest completed week returned -4.2%, after a 5.9% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0712-week average 0.04

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 5.9% over four weeks, -15.9% over 12 weeks, and -53.2% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-4.2%
4W5.9%
12W-15.9%
26W-18.0%
52W-53.2%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.07Latest activity-pressure read.
Pressure change68.5%Four-week change in activity pressure.
Leadership-51.13Latest relative-leadership reading.
RS change12.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 30 Apr 2026 Field coverage 58% Model confidence 58%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength67/100Blend of value, momentum, and quality. Underlying universe rank 34; rank 1 is best.
Value58/100Relative valuation strength. Underlying universe rank 43; rank 1 is best.
Quality59/100Profitability and accounting quality. Underlying universe rank 42; rank 1 is best.
Momentum59/100Medium-term price momentum. Underlying universe rank 42; rank 1 is best.
Growth61/100Revenue and earnings growth. Underlying universe rank 40; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-79.9%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
0/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-97.3%
Net share repurchases relative to market value.
Shareholder yield
-97.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 17 relevant articles.

1 positive · 16 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-76.4%Distance below the 52-week high.
13-week volatility12.7%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher12 of 2614 weeks finished lower.
Best week+22.6%Week of 10 Jul.
Worst week-27.9%Week of 15 May.
Latest week-4.2%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains3
Flat weeks0
Modest losses6
Sharp losses8
Recent vol12.7%13-week weekly-return volatility.
Base vol12.6%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew9.4% / -9.9%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape21/100

Trend, activity pressure, participation, and risk combine to a 21/100 tape read.

 Indicator analysis30/100

Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.

Activity pressure 0.07; No reversal markers Next-Week ExpectancyNegative 39.17%

Next-week expectancy is negative with a 39.17% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors60/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 100; Small Cap Core rank 46 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 17 relevant articles.

What's Going On With Briacell Therapeutics Corp Stock Monday? Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20264.82 CAD-4.2%5.38 CAD281.4 CAD1.07-51.1313.9KOff
24 Jul 20265.03 CAD-4.4%5.55 CAD289.8 CAD1.06-50.0414.1KOff
17 Jul 20265.26 CAD-5.7%5.76 CAD297.7 CAD1.02-48.4831.9KOff
10 Jul 20265.58 CAD22.6%6.00 CAD305.7 CAD0.87-46.3061.8KOff
3 Jul 20264.55 CAD4.6%6.26 CAD313.7 CAD0.64-58.5115.4KOff
26 Jun 20264.35 CAD5.8%6.64 CAD321.8 CAD0.64-63.115.9KOff
19 Jun 20264.11 CAD8.2%6.97 CAD329.7 CAD0.75-67.72300Off
12 Jun 20263.80 CAD-11.8%7.21 CAD337.3 CAD0.91-72.2910.7KOff
5 Jun 20264.31 CAD-14.3%7.51 CAD344.9 CAD1.08-70.2515.0KOff
29 May 20265.03 CAD5.0%7.90 CAD352.8 CAD1.14-68.0533.2KOff
22 May 20264.79 CAD16.0%8.24 CAD360.6 CAD1.18-71.3078.2KOff
15 May 20264.13 CAD-27.9%8.72 CAD368.2 CAD1.28-76.20165.4KOff
8 May 20265.73 CAD1.1%9.13 CAD376.1 CAD1.19-68.9121.1KOff
1 May 20265.67 CAD7.0%9.52 CAD384.5 CAD1.06-70.6746.0KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.